SCHEMBL21609149

SCHEMBL21609149

COc1cc(Br)ccc1S(=O)(=O)Nc1noc2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 7/20 0.66
BRD4 O60885 7/20 0.50
KAT7 O95251 6/20 0.50
KAT6B Q8WYB5 2/20 0.50
KMT2A Q03164 1/20 0.49
PKM P14618 1/20 0.49
EDNRB P24530 2/20 0.47
EDNRA P25101 2/20 0.47
CCNT1 O60563 1/20 0.45
CDK9 P50750 1/20 0.45
KAT5 Q92993 1/20 0.44
KAT8 Q9H7Z6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21609026 0.87 KAT6A (0.67) KAT6ABRD4KAT7KAT6BKMT2A
SCHEMBL21609131 0.86 KAT6A (0.62) KAT6ABRD4KAT7KAT6BPKM
SCHEMBL29652570 0.86 KAT6A (0.74) KAT6ABRD4KAT7KAT6BKMT2A
SCHEMBL21609129 0.86 KAT6A (0.74) KAT6ABRD4KAT7KAT6BKMT2A
SCHEMBL21609152 0.85 KAT6A (0.65) KAT6ABRD4KAT7KAT6BKMT2A
SCHEMBL31605598 0.85 KMT2A (0.58) KAT6ABRD4KMT2APKMEDNRB
SCHEMBL31605568 0.84 KAT6A (0.64) KAT6AKAT7KAT6BKMT2AKAT5
SCHEMBL21596818 0.84 KAT6A (0.64) KAT6AKAT7KAT6BKMT2AKAT5
SCHEMBL21596902 0.84 KAT6A (0.62) KAT6ABRD4KAT7KAT6BKMT2A
SCHEMBL29652431 0.84 KAT6A (0.62) KAT6ABRD4KAT7KAT6BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
EP-4335439-A2 COMPOUNDS CTXT PTY LTD (AU) 2024-03-13 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
WO-2019243491-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153710-A1 Compounds SLC10A1, ABCB11, PCSK9 KAT6A 877/4885BRD4 1909/4885KAT7 490/4885
US-20200039945-A1 Compounds SLC10A1, ABCB11, PCSK9 KAT6A 878/4885BRD4 1913/4885KAT7 490/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B KAT6A 160/4885BRD4 343/4885KAT7 271/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 KAT6A 878/4885BRD4 1913/4885KAT7 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.